JAAD Publishes Reply on Tofacitinib and Skin Sclerosis Data

The Journal of the American Academy of Dermatology has published, in its November 2026 issue, a research correspondence responding to a prior letter concerning real-world tofacitinib data in systemic sclerosis. The reply appears in Volume 95, Issue 5, under the authorship of Lu Yuan, Haochen Huang, Min Hui, Shihan Xu, and Dong Xu.

The exchange sits atop a chain of published correspondence. The original article, led by Huang and colleagues, analyzed national multicenter data from the Chinese Rheumatism Data Center (CRDC) to assess the real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis. Guo and colleagues then wrote a response questioning or commenting on aspects of that analysis. The newly published reply from Yuan, Huang, Hui, Xu, and Xu is the authors' answer to that critique.

Systemic sclerosis, an autoimmune connective tissue disease, features skin fibrosis — thickening and hardening of the skin — that physicians commonly track with the modified Rodnan skin score (mRSS), a measure of skin thickness at defined body sites. Tofacitinib is a Janus kinase (JAK) inhibitor, a drug class that blocks intracellular signaling pathways driving inflammation. The CRDC analysis examined whether the agent slows skin sclerosis progression outside controlled trial conditions.

What does the correspondence itself contain?

The published record available here identifies the reply's authors, its placement, and its position within the correspondence chain. It does not reproduce the substantive arguments: the specific methodological points raised by Guo et al, the statistical clarifications offered in response, or any revised effect estimates. Readers should treat any characterization of the reply's content beyond its existence and authorship as unverified until the full text is consulted.

This restraint matters. Correspondence exchanges over real-world datasets frequently turn on questions of confounding, cohort definition, and endpoint selection. Without the text, one cannot establish which of those issues the authors addressed.

Why the underlying study drew attention

The original Huang et al analysis drew on national multicenter registry data from the CRDC — a design that trades the internal validity of a randomized trial for evidence of how a drug performs across heterogeneous, routine-care populations. For a disease with limited approved therapeutic options for skin fibrosis, registry-grade evidence on a repurposed agent such as tofacitinib carries practical weight.

Peer correspondence of this kind serves a checking function: it subjects registry findings to scrutiny before they harden into clinical practice. A published reply indicates the authors chose to defend or clarify their work in the same forum.

What remains open

The November 2026 publication closes one round of exchange; it does not settle the question of tofacitinib's role in systemic sclerosis skin disease. Definitive positioning would require the controlled trial data that real-world analysis cannot substitute for. Clinicians following this literature should read the reply alongside both the original CRDC analysis and the Guo et al critique in JAAD Volume 95, Issue 5.